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OBJECTIVE—Theobjectiveofthisstudyistoexaminetherelationshipamongserumlevelsof
25-hydroxyvitamin D (25[OH]D), polymorphisms in vitamin D-associated genes, and the pres-
ence and progression of coronary artery calciﬁcation (CAC) in adults with type 1 diabetes.
RESEARCH DESIGN AND METHODS—This prospective study included 374 non-
Hispanic white individuals with type 1 diabetes (mean age 40 6 9 years; 46% were male).
CAC was measured at the baseline and 3- and 6-year follow-up visits were determined by
electron beam computed tomography. Serum 25[OH]D levels were measured by liquid chro-
matography tandem mass spectrometry at the 3-year visit.
RESULTS—Normal(.30ng/mL),insufﬁcient(20–30ng/mL),anddeﬁcient(,20ng/mL)25-
[OH]D levels were present in 65%, 25%, and 10% of the individuals with type 1 diabetes,
respectively. 25[OH]D deﬁciency was associated with the presence of CAC at the 3-year visit,
odds ratio (OR) = 3.3 (95% CI 1.6–7.0), adjusting for age, sex, and hours of daylight. In subjects
free of CAC at the 3-year visit, 25[OH]D deﬁciency predicted the development of CAC over the
next 3 years in those with the vitamin D receptor M1T CC genotype (OR = 6.5 [1.1–40.2], P =
0.04) than in those with the CT or TT genotype (OR = 1.6 [0.3–8.6], P = 0.57).
CONCLUSIONS—Vitamin D deﬁciency independently predicts prevalence and develop-
ment of CAC, a marker of coronary artery plaque burden, in individuals with type 1 diabetes.
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C
oronary artery disease (CAD) is the
major cause of morbidity and mor-
talityinpatientswithtype1diabetes
(1,2). Coronary artery calciﬁcation
(CAC), a marker of coronary artery
plaque burden, predicts coronary events
in persons with type 1 diabetes (3). The
presence and progression of CAC have
become useful surrogate CAD end points
inevaluatingnovelCADriskfactors(3,4).
Vitamin D deﬁciency has been asso-
ciatedwithincreasedriskofCAD(5–7)in
peoplewithoutdiabetes,aswellascardio-
vascular mortality (8). Studies have also
shown that vitamin D levels are lower in
individuals with type 1 diabetes (9,10),
although whether this relationship holds
for different geographic populations is
unclear (11).Vitamin Dregulates calcium
blood levels and affects vascular smooth
muscle cell proliferation (12), inﬂamma-
tion (13), and the renin-angiotensin sys-
tem(14),allofwhich havecardiovascular
effects and could lead to coronary calciﬁ-
cation.Serum levelof25-hydroxyvitamin
D (25[OH]D) assesses vitamin D status
best. 25[OH]D is the major circulating
form of vitamin D and the precursor of
the active form 1,25[OH]D. This active
form binds in the circulation to vitamin
D-binding protein (VDBP), to be trans-
ported to target organs where it mediates
its biological effects by binding to the vi-
tamin D receptor (VDR).
Cross-sectional studies of the rela-
tionship between 25[OH]D levels and
CAC have been inconclusive. A study of
650 Amish subjects found no association
(15); lower 25[OH]D levels were associ-
ated with carotid and aortal, but not with
coronary artery, calciﬁed plaques in 340
African Americans with type 2 diabetes
(16). The Multi-Ethnic Study of Athero-
sclerosis (MESA) study (17) reported that
lower 25[OH]D levels predicted develop-
ment of CAC, but not progression of
CAC. Our study examined the cross-
sectional and longitudinal relationship
between 25[OH]D levels and CAC in
adults with type 1 diabetes. We also ex-
plored whether the potential relationship
between 25[OH]D levels and CAC dif-
fered by polymorphisms in the VDBP
and VDR genes.
RESEARCH DESIGN AND
METHODS—The Coronary Artery
Calciﬁcation in Type 1 Diabetes (CACTI)
study population has been described pre-
viously(4).Inbrief,652men andwomen
with type 1 diabetes and 764 nondiabetic
control subjects aged 19–56 years, with
nohistoryofCAD,wereenrolledinapro-
spective follow-up of the development
and progression of CAC. Patients with
type 1 diabetes had long-standing diabe-
tes (mean duration 23 years, range 4–52
years) on enrollment. Control subjects
had not been diagnosed with diabetes of
any type, had fasting blood glucose in the
normal range, and were generally spouses,
friends, or neighbors of the patients. All
subjects provided informed consent, and
the study was approved by the Colorado
Multiple Institutional Review Board.
Participants were examined at a base-
line visit in 2000–2002. Data used in
these analyses are from the second (3-
year) and third (6-year) follow-up visits,
both conducted approximately 2.5 6 0.4
years after each prior visit. For these anal-
yses,allsubjects with type 1 diabetes who
had complete data at the 3-year visit were
i n c l u d e d .At o t a lo f3 7 4n o n - H i s p a n i c
white subjects with type 1 diabetes were
analyzed. Anthropometric measurements
were obtained, including height, weight,
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ORIGINAL ARTICLEminimalwaistcircumference,andhipcir-
cumference. BMI was calculated in kilo-
grams/meters squared. Resting systolic
blood pressure and ﬁfth-phase diastolic
blood pressure were measured three
times while the patients were seated
after a 5-min rest, and the second and
third measurements were averaged. Hy-
pertension was deﬁned as a blood pres-
sure $140/90 mmHg or participant
receiving current antihypertensive treat-
ment. Current medication, tobacco use,
and family medical history were obtained
bystandardizedquestionnaire.VitaminD
and calcium intake were obtained by a
validated food frequency questionnaire
(Harvard 1988) and included the use of
supplements.
Laboratory measures
Total, HDL-cholesterol, and triglycerides
were measured by standard enzymatic
methods, and LDL-cholesterol was calcu-
latedbytheFriedewaldformula.Albumin
excretion rate (AER) was calculated from
urinary albumin measured in two timed
overnight urine samples, and the results
from the two nights were averaged. 25
[OH]D levels were measured by liquid
chromatography tandem mass spectrom-
etry by Quest Diagnostics on samples
collected at the 3-year visit. Season of
blooddrawwasclassiﬁedasfall/winterfor
blood drawn during the months of Octo-
ber to March and spring/summer as April
toSeptember,andthenumberofhoursof
average daylight over the 2 weeks before
the study visit was calculated on the basis
ofstudydateandlatitudeofthestudyvisit
(Denver,CO,latitude39°45’N).Individ-
uals were categorized as vitamin D sufﬁ-
cient (25[OH]D .30 ng/mL), insufﬁcient
(20–30 ng/mL), or deﬁcient (,20 ng/mL),
according to current clinical guide-
lines (18).
Genomic DNA was extracted from
leukocytes by the salting out method.
Vitamin D-binding protein (VDP)g e n e
polymorphisms 420 (C/A) and 416 (T/G)
and vitamin D receptor (VDR)g e n ep o l y -
morphism M1T (T/C) and Bsm1 (G/A)
were genotyped in a multiplex dot-blot
sequence-speciﬁc oligonucleotide poly-
merase chain reaction (SSO-PCR) assay
(RocheMolecularSystems,Pleasanton,CA).
Coronary artery calciﬁcation
Two sets of high-resolution noncontrast
contiguous 3-mm tomographic images
were acquired at 0.1-s exposure on an
Imatron C-150XLP electron-beam CT
scanner (Imatron, San Francisco, CA) as
described previously (4). The two sets of
scans were acquired within 5 min, and
CAC scores were averaged. Calcium vol-
ume scores (CVS) were square root trans-
formed, and the difference in square
root transformed CVS between the
3- and 6-year examinations was calcu-
lated. Progression of CAC was deﬁned
a sac h a n g ei ns q u a r er o o tt r a n s f o r m e d
CVS of $2.5 (19).
Statistical analyses
All statistical analyses were conducted in
the SAS 9.2 system (SAS Institute, Cary,
NC). Statistical signiﬁcance was deﬁned
as P , 0.05. The association of 25[OH]D
level with genotype was determined af-
ter adjustment for age, sex, hours of
daylight, AER, vitamin D intake, and cal-
cium intake. The association of vitamin D
deﬁciencywiththepresenceofCACatthe
3-year follow-up visit was examined in a
multiple logistic regression model ini-
tially adjusted for age, sex, and hours of
daylight. Additional models were run ad-
justing for BMI, HDL-cholesterol, LDL-
cholesterol, and triglycerides. Models
adjusted for factors that may affect vita-
min D levels (AER, total vitamin D intake,
and total calcium intake) were also run to
examinetheprecisionofourestimates.Ge-
notypic data were added to these models.
The effect of vitamin D deﬁciency on
progression of CAC from the 3- to 6-year
visit was examined in a multiple logistic
regression model adjusted for age, sex,
Table 1—Characteristics of study participants with type 1 diabetes at the 3-year visit
Subjects with type 1 diabetes (N =3 7 4 )
25[OH]D level (ng/mL): mean 6 SD (median) 35.4 6 13.0 (34.0)
Vitamin D status
Normal (.30 ng/mL) 244 (65.2%)
Insufﬁcient (20–30 ng/mL) 92 (24.6%)
Deﬁcient (,20 ng/mL) 38 (10.2%)
Age at 3-year visit: mean 6 SD (median) 39.7 6 8.9 (39.7)
Female 202 (54.0%)
Male 172 (46.0%)
BMI (kg/m
2): mean 6 SD (median) 26.2 6 4.3 (25.5)
Current smoker†
Yes 29 (8.3%)
No 321 (91.7%)
Total cholesterol (mg/dL) 175.7 6 32.2 (172.3)
HDL-cholesterol (mg/dL) 62.3 6 19.5 (59.0)
LDL-cholesterol (mg/dL) 99.3 6 26.6 (98.2)
Triglycerides (mg/dL) 70.2 6 47.4 (59.0)
Systolic blood pressure (mmHg) 111.6 6 12.6 (110.0)
Diastolic blood pressure (mmHg) 74.2 6 8.7 (74.0)
HypertensiveU
Yes 175 (46.9%)
No 198 (53.1%)
Coronary artery calciﬁcation
Yes 170 (45.5%)
No 204 (54.5%)
VDR 420 CC 196 (59.2%)
CA 111 (33.5%)
AA 24 (7.3%)
VDR 416 TT 132 (41.1%)
TG 126 (39.3%)
CC 63 (19.6%)
VDR M1T TT 64 (17.1%)
CT 178 (47.6%)
CC 132 (35.3%)
VDR Bsm1 GG 123 (32.9%)
GA 178 (47.6%)
AA 73 (19.5%)
†Smoking status is missing for 25 participants. ¥Hypertensive is deﬁned as blood pressure $140/90 mmHg
or current hypertensive treatment. Hypertensive is missing for two participants.
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Young and Associateshours of daylight, presence of CAC at the
3-year visit, AER, total vitamin D intake,
and total calcium intake. An interaction
termforvitaminDdeﬁciencyandpresence
of CAC at the 3-year visit was included to
examineincidentcomparedwithprevalent
CAC. In addition, an interaction term for
vitamin D deﬁciency and the VDR geno-
type M1T was included to explore a possi-
bility of gene–environment interaction on
CAC progression.
RESULTS—Characteristics of study
participants at the 3-year visit are sum-
marizedinTable1.Age-andsex-adjusted
mean 25[OH]D levels for type 1 diabetes
subjects were 35.4 6 0.7 ng/mL. Normal
(.30 ng/mL), insufﬁcient (20–30 ng/mL),
and deﬁcient (,20 ng/mL) 25-[OH]D lev-
els were present in 65%, 25%, and 10% of
the patients with diabetes, respectively.
Polymorphisms in the VDP and VDR
genes were associated with levels of 25
[OH]D after adjusting for age, sex, hours
of daylight, AER, total vitamin D intake,
andtotalcalciumintake(Fig. 1).Levelsof
25[OH]D were higher among individuals
withtheCC(37.661.0ng/mL)genotype
at VDP420 compared with those with the
CA (34.3 6 1.2 ng/mL, P = 0.03) and AA
(32.3 6 2.8 ng/mL, P = 0.08) genotypes.
At VDP 416, levels of 25[OH]D were sig-
niﬁcantly higher among individuals with
the TT (38.4 6 1.0 ng/mL) genotype
compared with those with the TG
(35.1 6 1.2 ng/mL, P =0 . 0 4 )a n d
GG (32.7 6 1.1 6 1.7 ng/mL, P =
0.007) genotypes. Of the polymorphisms
studied in the VDR gene, only those at
VDRM1Tshowedsigniﬁcantassociations
with level of 25[OH]D. Levels of 25[OH]
Dw e r es i g n i ﬁcantly higher among indi-
viduals with the TT (40.0 6 1.7 ng/mL)
genotype at VDR M1T compared with
those with the CT (36.0 6 1.1 ng/mL,
P = 0.05) and CC (33.7 6 1.0 ng/mL,
P = 0.002) genotypes.
Lower levels of vitamin D as a contin-
uousmeasureweresigniﬁcantlyassociated
with presence of CAC at the 3-year visit,
adjusting for age, sex, and hours of day-
light (odds ratio [OR] = 0.98 [95% CI
0.96–1.00; P = 0.02]). Additional ad-
justment for BMI, HDL-cholesterol,
LDL-cholesterol, and triglycerides
attenuated these results (OR = 0.99
[0.97–1.00]; P = 0.21).
Vitamin D deﬁciency (25[OH]D ,20
ng/mL) was associated with the presence
of CAC at the 3-year visit (OR = 3.3 [95%
CI 1.6–7.0; P = 0.002]),adjusting forage,
gender, and hours of daylight (Table 2).
Similar results were found when examin-
ing the same models with vitamin D
insufﬁciency (,30 ng/mL) (OR = 1.8
[1.1–3.0]). Additional adjustment for
BMI, HDL-cholesterol, LDL-cholesterol,
and triglycerides did not signiﬁcantly af-
fect the association with vitamin D deﬁ-
ciency and CAC (OR = 2.4 [1.1–5.3]. The
addition of factors that could affect vita-
min D levels (AER, vitamin D intake, and
calcium intake) attenuated the results
only slightly (2.2 [0.8–5.8]). Adjustment
for VDP 420, VDP 416, VDR M1T, and
VDR Bsm1 did not change these ﬁndings.
Figure 1—Vitamin D levels by genotype. Least square means adjusted for age, sex, diabetes status, hours of daylight, AER, vitamin D intake,
and calcium intake. Upper left, VDP 420; upper right, VDP 416; lower left, VDR M1T; lower right, VDR Bsm1. *P , 0.05 compared with major
genotype.
Table 2—Association of vitamin D deﬁciency and presence of CAC at 3-year visit
Model
Vitamin D deﬁciency
(yes vs. no)
OR (95% CI)
Model 1: Adjusted for age, sex, and hours of daylight 3.3 (1.6–7.0)
Model 1 + AER, vitamin D intake, and total calcium intake 2.8 (1.1–7.0)
Model 1 + BMI, HDL-cholesterol, LDL-cholesterol, and triglycerides 2.4 (1.1–5.3)
Model 1 + BMI, HDL-cholesterol, LDL-cholesterol, triglycerides, AER,
vitamin D intake, and total calcium intake 2.2 (0.8–5.8)
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Vitamin D and coronary calciﬁcationNo polymorphisms were associated with
the presence of CAC at the 3-year visit.
In the longitudinal analyses of the
relationship between vitamin D deﬁ-
ciency and progression of CAC, we ﬁrst
explored if the effect of vitamin D de-
ﬁciency differed between persons free of
CACandthosewhoalreadyhaddetectable
CAC at the 3-year visit. The interaction
term was borderline signiﬁcant (P = 0.06),
indicating that vitamin D-deﬁcient sub-
jects without preexisting CAC at the
3-year visit were more likely to develop
CAC than those with sufﬁcient vitamin
D levels, whereas vitamin D-deﬁcient
subjects with CAC already present did
not experience more CAC progression
thanthosewithsufﬁcientvitaminDlevels.
T h em u l t i v a r i a t em o d e lt h a tt a k e s
into account the interactions among vita-
min D deﬁciency, presence/absence of
CAC at 3-year visit, and VDR M1T geno-
type is shown in Table 3. Vitamin D de-
ﬁciency predicted development of CAC
among subjects free of CAC at the 3-
year visit. Among those, vitamin D deﬁ-
ciency was a stronger risk factor for CAC
in the presence of the VDR M1T CC ge-
notype (OR = 6.5 [1.1–40.2], P = 0.04)
than in the presence of the CT or TT ge-
notype (OR = 1.6 [0.3–8.6], P = 0.57).
Vitamin D deﬁciency did not predict pro-
gressionofCACamongsubjectswithpre-
existing CAC at the 3-year visit.
CONCLUSIONS—The results of this
study are consistent with the growing
body of evidence for the role of vitamin D
deﬁciency in development of coronary
atherosclerosis. They are also internally
consistent with regard to cross-sectional
and longitudinal analyses. The novel
ﬁndings include demonstration of a po-
tential gene–environment interaction ef-
fect between the VDR M1T CC genotype
and vitamin D deﬁciency on CAC devel-
opment. Furthermore, these results indi-
cate that vitamin D deﬁciency may be of
particular importance during the early
events leading to development of coro-
nary calciﬁcation.
The only other prospective study
(The Multi-Ethnic Study of Atherosclero-
sis [MESA]) has also found that lower 25
[OH]D levels predicted incident but not
prevalent CAC (17). Both studies used
similar methods to measure CAC. 25
[OH]D was measured by radioimmuno-
assay in MESA and by high-performance
liquid chromatography in our study;
however,bothstudiesfoundsimilarprev-
alence of vitamin D deﬁciency (10% with
,20 ng/mL in our study and 10% with
,15 ng/mL in MESA). Dietary vitamin D
intake was available in CACTI and in-
cluded in our analyses, but not in the re-
port from MESA. In contrast with the
MESA study population, the CACTI
participants analyzed all had type 1 di-
abetes. Furthermore, the age of vitamin
D-deﬁcient CACTI participants was lower
(40.168.9years)thanthatofthoseinthe
MESA study (62.1 6 10.3 years). Despite
these differences in CACTI and MESA
study populations, results were remark-
ably similar, indicating a robust role of
vitaminDdeﬁciencyinCACdevelopment.
Our study population was limited to
non-Hispanic white subjects,whereasthe
MESA study (17) had a more diverse
study population. African Americans
and Hispanics have an increased preva-
lence of vitamin D deﬁciency; however,
the MESA study did not ﬁnd any differ-
ences by race (17). Results of our study
demonstrate that the effects of vitamin D
deﬁciency on CAC may be modiﬁed by
genetic factors, especially the VDR M1T
polymorphism. In our population, the
CC genotype, associated with the low-
est levels of serum 25[OH]D, conferred
increased risk of CAC development
indicating a possible pathway. This ﬁnd-
ing also is consistent with a previously
reported association between the CC ge-
notype and acute coronary syndrome
(20). Future studies should expand our
understanding of the genetic architecture
of vitamin D metabolism and its implica-
tions to atherosclerosis.
Our study has some limitations that
shouldbenoted.Becausewemeasured25
[OH]D levels only at the 3-year visit, we
do not know whether this measure is a
stable indicator of overall vitamin D sta-
tus. We only studied subjects with type 1
diabetes, so we are uncertain if these
ﬁndings differed between subjects with
and without type 1 diabetes. Our study
was also underpowered to test gene–
environment interactions of modest mag-
nitude,soitispossiblethatsuchinteractions
exist but were not detected in this study.
IntheCACTIstudy,theassociationof
vitamin D deﬁciency with prevalent CAC
was independent of known CAD risk
factors, including confounders such as
BMI and mediators such as lipids. This
suggeststhatvitaminDmaynotberelated
to CAD through common pathways with
these traditional CAD risk factors but
rather through a unique biologic mecha-
nism. Vitamin D regulates the renin-
angiotensin system (14) and may lower
cardiovascular risk through this mecha-
nism. Cardioprotective effects of 1,25
[OH]2D treatment have been demon-
s t r a t e di na n i m a lm o d e l s( 2 1 –23). Our
results suggest that vitamin D deﬁciency
may be involved in the initiation of coro-
nary calciﬁcation process. Vitamin D has
an effectonantigen-presentingcells,such
as dendritic cells and macrophages, and
treatment with 1,25[OH]2D can reduce
foamy macrophages and suppress choles-
terol uptake (24).
In conclusion, this study has
strengthened the evidence for the role of
vitamin D deﬁciency in the development
of coronary atherosclerosis, especially
during the early events leading to devel-
opment of coronary calciﬁcation. The
novel ﬁndings include demonstration of
this effect in patients with type 1 diabetes
and evidence for a gene–environment in-
teraction between the VDR M1T CC ge-
notype and vitamin D deﬁciency on CAC
development.
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vitamin D intake, total calcium intake, and AER.
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